UCB wins FDA ap­provals in plaque pso­ri­a­sis and gMG, un­lock­ing block­buster op­por­tu­ni­ties

UCB’s treat­ment can­di­dates for plaque pso­ri­a­sis and gen­er­al­ized myas­the­nia gravis have both bagged ap­provals in the US, ex­pand­ing cur­rent mar­ket op­por­tu­ni­ties and open­ing up new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER